Opendata, web and dolomites

GLIOMA

Targeting Glioblastoma using Combinatorial Therapeutic Nanovaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GLIOMA project word cloud

Explore the words cloud of the GLIOMA project. It provides you a very rough idea of what is the project "GLIOMA" about.

appropriate    bacterial    cd133    activation    contain    antigen    chemo    coated    alter    stimulate    lines    permanently    gbm    synthesis    amount    pharmacokinetic    functionalised    characterised    murine    examinations    macrophage    models    recognizes    gold    encapsulating    core    microscopic    outcomes    cytokine    tnvax    therapeutic    immuno    disease    facilitates    vivo    monoclonal    holds    channel    memory    subjected    l1    functionalisation    therapeutically    tmz    temozolamide    antibody    performed    caused    techniques    kinetics    pharmacodynamic    combinatorial    particles    encapsulated    suffer    cytotoxicity    nps    nanocage    immunofluorescence    histopathological    extremophilic    leaving    anti    site    antitumour    cell    glioblastoma    payload    immune    polysaccharide    spectroscopic    drug    pd    evaluations    synthesised    offers    binding    nanoparticles    thereby    vitro    multiforme    nanovaccine    immunological    facs    multiple    host    interactions    tumour    nvax    eradicating    killing    mauran    induction    patients    release    formulation    suppression    characterisation    significantly    cells    modules    good   

Project "GLIOMA" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF BRIGHTON 

Organization address
address: LEWES ROAD MITHRAS HOUSE
city: BRIGHTON
postcode: BN2 4AT
website: www.brighton.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.brighton.ac.uk/research-and-enterprise/groups/biomaterials-and-medical-devices/glioma.aspx
 Total cost 195˙454 €
 EC max contribution 195˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-10-02   to  2019-10-01

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF BRIGHTON UK (BRIGHTON) coordinator 195˙454.00

Map

 Project objective

The proposal aims at the synthesis, characterisation and application of a novel therapeutic nanovaccine (TNVax) that holds multiple modules for targeting glioblastoma multiforme (GBM). The proposed TNVax formulation includes a gold nanocage core encapsulating Temozolamide (TMZ), coated with an extremophilic bacterial polysaccharide, mauran functionalised with anti-PD-L1 antibody and anti-CD133 antibody. The us of NVax nanoparticles (NPs) offers a combinatorial approach in killing GBM cells both by immuno- and chemo- therapeutically. Site-specific delivery of the payload will stimulate the host immune system and channel the immune cells to the target site. Functionalisation of the anti-PD-L1 antibody on drug-encapsulated NPs would significantly alter the immune suppression caused by GBM cells on TNVax delivery. In addition to anti-PD-L1 antibody, the TNVax particles contain tumour specific monoclonal antibody that specifically recognizes CD133 antigen and facilitates strong binding. This approach would enhance the amount of antitumour activity offered by multiple means and thereby leaving a strong immune response against GBM based on antigen-antibody interactions. TNVax NPs will be synthesised and characterised using microscopic and spectroscopic techniques and then subjected to in vitro and in vivo evaluations. In vitro studies will be performed for drug release kinetics and cytotoxicity using immunofluorescence and FACS analysis. Induction of immune response by TNVax NPs will be evaluated using macrophage activation, induction of T-cell activity and cytokine production under in vitro conditions. The pharmacokinetic and pharmacodynamic studies will be carried out and histopathological examinations performed using appropriate murine models induced with GBM cell lines. The potential outcomes of the proposed studies will help patients who suffer from early and advanced GBM by eradicating the disease permanently and leaving good immunological memory.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIOMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CLIMACY (2020)

Practices of Climate Diplomacy and Uneven Policy Responses on Climate Change on Human Mobility

Read More  

DIGILEAD (2020)

Digital leadership, well-being and performance in organizations

Read More  

Cartesian Networks (2020)

Cartesian Networks in Early Modern Europe: A Quantitative and Interdisciplinary Approach

Read More